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ABSTRACT Artemisinin-based combination therapies (ACTs) have been vital in reduc-
ing malaria mortality rates since the 2000s. Their efficacy, however, is threatened by the
emergence and spread of artemisinin resistance in Southeast Asia. The Plasmodium falci-
parum multidrug resistance protein 1 (PfMDR1) transporter plays a central role in para-
site resistance to ACT partner drugs through gene copy number variations (CNV) and/or
single nucleotide polymorphisms (SNPs). Using genomic epidemiology, we show that
multiple pfmdr1 copies encoding the N86 and 184F haplotype are prevalent across
Southeast Asia. Applying genome editing tools on the Southeast Asian Dd2 strain and
using a surrogate assay to measure transporter activity in infected red blood cells, we
demonstrate that parasites harboring multicopy N86/184F PfMDR1 have a higher Fluo-4
transport capacity compared with those expressing the wild-type N86/Y184 haplotype.
Multicopy N86/184F PfMDR1 is also associated with decreased parasite susceptibility to
lumefantrine. These findings provide evidence of the geographic selection and expan-
sion of specific multicopy PfMDR1 haplotypes associated with multidrug resistance in
Southeast Asia.
IMPORTANCE Global efforts to eliminate malaria depend on the continued success
of artemisinin-based combination therapies (ACTs) that target Plasmodium asexual
blood-stage parasites. Resistance to ACTs, however, has emerged, creating the
need to define the underlying mechanisms. Mutations in the P. falciparum multi-
drug resistance protein 1 (PfMDR1) transporter constitute an important determi-
nant of resistance. Applying gene editing tools combined with an analysis of a
public database containing thousands of parasite genomes, we show geographic
selection and expansion of a pfmdr1 gene amplification encoding the N86/184F
haplotype in Southeast Asia. Parasites expressing this PfMDR1 variant possess a
higher transport capacity that modulates their responses to antimalarials. These
data could help tailor and optimize antimalarial drug usage in different regions
where malaria is endemic by taking into account the regional prevalence of
pfmdr1 polymorphisms.
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In 2018, an estimated 228 million cases of malaria, predominantly in sub-SaharanAfrica, resulted in 405,000 deaths worldwide, mostly in children less than five years
old. Plasmodium falciparum is responsible for most of the global malaria burden. Over
the past 2 decades, impressive gains have been made in the reduction of global malaria
morbidity and mortality rates, which stood at an estimated one million deaths per year
in the early 2000s (1). The widespread adoption of artemisinin (ART)-based combination
therapies (ACTs) and increased population-level coverage of insecticide-treated bed
nets to protect against infective Anopheles mosquito vectors have been important
contributors in the fight against malaria (2, 3). Unfortunately, the emergence and
spread of ART- and ACT partner drug-resistant P. falciparum lineages in the Greater
Mekong subregion of Southeast Asia (4–9) and in South America (10, 11) during the
past decade pose a significant threat to malaria control and elimination. Efforts are
under way to contain the spread of ART resistance into Africa and India (12–14) where
it is predicted to have devastating results (15), as happened earlier with the emergence
and global spread of chloroquine (CQ) resistance (8, 16, 17).
One important mediator involved in multidrug resistance to ACTs is the ATP-binding
cassette (ABC) transporter P. falciparum multidrug resistance protein 1 (PfMDR1).
PfMDR1 is localized in the membrane of the digestive vacuole (DV) of the parasite and
possesses the ability to influx antimalarial drugs toward the lumen of this organelle
(18–20). Transport studies using heterologous expression systems have shown that
PfMDR1 variants have the ability to modulate the transport of the antimalarial drugs
halofantrine and quinine (QN) (21). A surrogate assay of PfMDR1 activity using the
fluorochrome Fluo-4 revealed its subcellular distribution and showed that PfMDR1-
mediated solute import into the parasite DV is modulated by at least three C-terminal
codon variants (S1034C, N1042D, and D1246Y) (22, 23). The pfmdr1 N-terminal allelic
variants N86Y and Y184F have also been implicated in multidrug-resistant phenotypes.
In Africa and Asia, the N86 allele is relevant for in vivo and in vitro parasite antimalarial
responses against aryl-amino alcohols such as mefloquine (MFQ) (24, 25) and lumefan-
trine (LMF) (26–28). In clinical trials of artemether-LMF or artesunate plus amodiaquine
(ADQ), an increased risk of posttreatment recrudescent P. falciparum infections was
associated with parasites harboring the N86 wild-type or 86Y mutant allele, respectively
(29). These in vivo observations have been supported by recent allelic exchange
approaches (30). Mutations in pfmdr1 have a drug-specific resistance contribution
being “pro and con” depending on the antimalarial. Compared to pfmdr1 N86Y, the
impact of the Y184F mutation on parasite responses to ACTs remains less studied (31).
This mutation is one of the five canonical PfMDR1 mutations that was earlier considered
to be associated with chloroquine resistance (32) and is now widespread in Southeast
Asia and Africa (33–36). The capacity of 184F to influence parasite antimalarial re-
sponses is thought to be related to alterations in protein structure through allosteric
effects that reduce drug binding or alter transport kinetics (20).pfmdr1 copy number
variation (CNV) is another important factor that impacts parasite susceptibility to
several antimalarial drugs (18). P. falciparum parasites harboring pfmdr1 amplifications
are widely distributed in South America (37) and Southeast Asia (24, 25). Amplification
of pfmdr1 is associated with an increased risk of treatment failure with therapies
combining an aryl-amino alcohol such as MFQ or LMF with an ART derivative (25,
38, 39).
Using data from the updated MalariaGEN Plasmodium falciparum Community Proj-
ect (40), we explored the prevalence and distribution of pfmdr1 copy numbers encod-
ing specific haplotypes. We show that pfmdr1 gene amplification is especially common
in Southeast Asia, with amplifications being selected along with the N86 and 184F
alleles. Applying genome editing tools on the 86Y- and Y184-harboring Southeast Asian
Dd2 strain, we demonstrate that the N86/184F haplotype in the context of amplified
pfmdr1 imparts a higher transport capacity that directly affects parasite antimalarial
responses.
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RESULTS
Temporal distribution of PfMDR1 haplotypes and copy number variants in
Southeast Asia. We determined the worldwide frequencies of pfmdr1 N86Y and Y184F
mutations and pfmdr1 copy number using a collection of 7,113 parasite genomes from
the MalariaGEN P. falciparum Community Project version 6 (https://www.malariagen
.net/resource/26) (40). Genomic data were available from 73 countries where malaria is
endemic with information on pfmdr1 N86Y and Y184F mutations, as well as pfmdr1
copy number, in a subset of 5,003 samples. From that subset, 650 had pfmdr1
amplifications. Of these, 53 were excluded from further frequency analysis due to the
presence of multiple alleles at codon positions 86 and/or 184, indicating the presence
of mixed infections (see Table S1 in the supplemental material).pfmdr1 allele frequency
data were extracted from the MalariaGEN Community Project during the period from
2002 to 2015, revealing that the pfmdr1 N86Y mutation frequency has remained
relatively constant in Southeast Asia, with the N86 allele nearly fixed at a frequency of
96 to 98% (N86 allele frequency, 98% between 2002 and 2007, 98% between 2008 and
2010, 99% between 2011 and 2013, and 96% between 2014 and 2015). In Africa, the
N86 allele frequency has increased, whereas 86Y has decreased over the same time
period (see Fig. S1 in the supplemental material). In contrast to the fixation of the N86
allele in Southeast Asia, the frequency of the 184F variant has increased within the
same time frame (21% between 2002 and 2007, 30% between 2008 and 2010, 40%
between 2011 and 2013, and 59% between 2014 and 2015), leading to the selection of
the N86/184F haplotype in Southeast Asia between 2002 and 2015 (Fig. S1).
The MalariaGEN Community Project data also showed that pfmdr1 amplifications are
the most prevalent in Southeast Asia, with only one African isolate reported in 2009
from Ghana harboring two pfmdr1 copies encoding a N86/Y184 haplotype (Table S1).
In Southeast Asia, infections with P. falciparum isolates harboring pfmdr1 amplifications
were most prevalent in Thailand (52%), followed by Cambodia, Myanmar, and Vietnam
(15%, 14%, and 6%, respectively) (Fig. 1A). In Cambodia, the frequency of isolates with
pfmdr1 amplifications decreased progressively from 48% (12/25 isolates) during 2002 to
2007 to 25.6% (69/269 isolates) during 2008 to 2010 and 9.6% (55/572 isolates)
between 2011 and 2013) (41, 42). In contrast to Cambodia, the frequency of isolates
with pfmdr1 gene amplifications in Thailand showed an increasing trend over the same
period (45% [104/229] during 2002 to 2007, 47% [144/306] during 2008 to 2010, and
61% [168/275] during 2011 to 2013). Genomes containing pfmdr1 amplifications en-
coding the N86 allele predominated (97.8%), with only three isolates identified in
Cambodia carrying amplified copies of the pfmdr1 86Y variant (3/136 genomes) (Fig. 1B
and Table S1).
In Cambodia, the 184F allele frequency in isolates also carrying multiple copies of
the pfmdr1 N86 allele has increased (25% [3/12] between 2002 and 2007% to 62%
[43/69] between 2008 and 2010 and 85% [47/55] between 2011 and 2013). In contrast,
in Thailand, the 184F allele frequency has remained stable in isolates containing
multicopy pfmdr1 over the years (8% [8/104] between 2002 and 2007% to 6% [8/144]
between 2008 and 2010 and 10% [17/168] between 2011 and 2013). Limited or no
genome data were available from Vietnam and Myanmar between 2002 and 2010,
precluding the analysis of haplotype selection over time in these countries (Fig. 1B and
Table S1).
Together, these results show that pfmdr1 amplification is especially common in
Southeast Asia, with amplifications encoding the N86 and 184F residues being selected.
Amplified pfmdr1-edited parasites at codons 86 and 184. We developed a
targeted gene editing approach to study the impact of haplotype-specific increases in
pfmdr1 copy number on P. falciparum. Parasite lines derived from Southeast Asian P.
falciparum isolates from the 1980s, like Dd2, characteristically contain the 86Y allele. To
investigate the advantage of the predominant genotypes observed in Southeast Asia
described above (pfmdr1 amplifications containing haplotypes N86/184F or N86/Y184),
we performed gene editing in all pfmdr1 gene copies present in Dd2 parasites. Our Dd2
line represents a MFQ-resistant clone carrying four pfmdr1 copies isolated from the
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W2mef line, originally derived from the Southeast Asian CQ-resistant parasite strain W2
(harboring a single copy of pfmdr1) upon extended culture with MFQ for 96 weeks (43).
Dd2 and W2 parasites express the PfMDR1 86Y/Y184 haplotype and the CQ resistance-
conferring CVIET haplotype of the P. falciparum chloroquine resistance transporter
(PfCRT) (Table 1) (44, 45).
Using the previously described zinc-finger nuclease (ZFN) strategy to engineer
pfmdr1 mutations at codons 86 and 184, we successfully generated the Dd2 edited
lines, NFDd2 and NYDd2, each maintaining four copies of pfmdr1 encoding the N86/184F
and N86/Y184 haplotypes, respectively (Table 1 and Fig. 2A and B). These edited lines
represent the two major geographic variants of pfmdr1 present in Southeast Asia and
include gene amplifications. The presence of pure N86/184F and N86/Y184 haplotypes
in NFDd2 and NYDd2 lines, respectively, was confirmed by Sanger sequencing (Fig. 2C).
Quantitative PCR analysis demonstrated that the edited NFDd2 and NYDd2 lines main-
tained four copies of pfmdr1 as present in the unedited Dd2 parental strain (Fig. 2D).
Attempts to engineer parasites expressing the 86Y/184F haplotype failed. We verified
that this haplotype combination was not found among the 597 parasite genomes
harboring amplified copies of pfmdr1 in the MalariaGEN Community Project data set
FIG 1 Geographical distribution of amplified pfmdr1 gene copies and haplotype selection in Southeast Asia. Genetic
analysis used data generated by the recently updated MalariaGEN Plasmodium falciparum Community Project (version 6;
https://www.malariagen.net/resource/26) (40), comprising genomes with information on pfmdr1 copy number, single
nucleotide polymorphisms (SNPs), and no evidence of mixed infections. (A) Country shadings show the frequency of
genomes with amplified pfmdr1 copies (number of amplified pfmdr1 copies/total number of genomes) collected between
2002 and 2015. (B) Pie charts represent different PfMDR1 haplotypes present in genomes containing multiple pfmdr1 gene
copies (per country data are shown in Table S1 in the supplemental material) and stratified into three intervals of time
(2002 to 2007, 2008 to 2010, and 2011 to 2013). No samples were available for the years 2014 and 2015. The N86/184F
haplotype frequency is shown with 95% confidence intervals in parentheses below each pie chart. Empty pie charts
represent time periods in countries where no data were available.
TABLE 1 pfmdr1 and pfcrt polymorphisms of gene-edited and parental P. falciparum
laboratory strains
Parasite Plasmid
pfmdr1 polymorphisms pfcrt polymorphisms
CNV 86 184 1034 1042 1246 72 73 74 75 76
NFDd2 pmdr1NFa 4 N F S N D C V I E T
NYDd2 pmdr1NYa 4 N Y S N D C V I E T
Dd2 4 Y Y S N D C V I E T
W2 1 Y Y S N D C V I E T
aPlasmids were previously constructed (30). CNV, copy number variation.
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(Table S1). These findings suggest that the presence of the 86Y/184F haplotype in
amplified pfmdr1 copies might render the parasites nonviable or might confer a survival
disadvantage to the parasite population.
Fluo-4 transport into the parasite DV is altered by amplified PfMDR1 haplo-
types. We evaluated the influence of pfmdr1 polymorphisms at codons 86 and 184 on
PfMDR1 functional activity by measuring the accumulation of Fluo-4 in the DVs (22) of
the gene-edited parasite lines (NFDd2 and NYDd2) compared to the Dd2 parental control
strain.
Accumulation of Fluo-4 in the DVs of NFDd2, NYDd2, and Dd2 parasites was observed
by fluorescence microscopy and measured by flow cytometry (Fig. 3). Fluo-4 accumu-
lation in the DV of the parasite was detectable after 120 min of incubation, prior to
which time the probe was distributed throughout the infected red blood cell (RBC) and
parasite cytosol (Fig. S2).
FIG 2 Schematic representation of the ZFN-based pfmdr1 editing strategy. (A) The plasmids pmdr1NY and pmdr1NF (30)
harbor a pair of pfmdr1-specific ZFNs (ZFN left [ZFN L] and ZFN right [ZFN R]) separated by a 2A skip peptide that drives
their polycistronic expression from the calmodulin promoter (cam), and the human dhfr (hdhfr) selectable marker. The
ZFNs induce a double-strand break (orange thunderbolt) 42 bp downstream of the pfmdr1 start codon, which is repaired
by homologous recombination with the 2.4-kb pfmdr1 donor sequence present on the plasmid. The pfmdr1 donor
sequence from pmdr1NY and pmdr1NF plasmids contains the N86/Y184 or N86/184F genotypes, respectively, and carries
three synonymous mutations (nucleotides colored in green) at the ZFN binding site to prevent ZFNs from cleaving the
plasmids or the pfmdr1-edited sequences. Two of the three synonymous mutations create a SmlI restriction site and abolish
a BstEII restriction site present in the nonedited (genomic) template. (B) PCR-RFLP genotyping confirming the presence of
pfmdr1-edited lines NYDd2 and NFDd2. The silent mutations introduced into the donor sequence created a SmlI restriction
site, which was used to screen PCR products (yielding a 1.3-kb band with P3 and P4 primers, which formed a doublet at
667/669 bp in edited parasites upon SmlI digestion). BstEII cuts the P3 and P4 PCR product in nonedited parasites and was
used as a control; the observed 1.3-kb band was not cut, indicating the presence of correctly edited parasites. (C) Sanger
sequencing chromatograms of DNA samples from the NYDd2 and NFDd2 edited lines at the pfmdr1 locus, confirming correct
editing at codons 86 and 184. (D) Plot showing means plus standard errors of the means (SEM) (error bars) from three
independent assays of pfmdr1 copy number, analyzed through quantitative PCR using -tubulin as a control gene and the
3D7 strain as a calibrator with a single pfmdr1 copy.
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Time variances in Fluo-4 transport associated with the PfMDR1 N86/184F and
N86/Y184 haplotypes in the edited parasite lines were measured by applying a linear
regression model from 120 min to 240 min (Fig. 3B). We observed a higher positive
slope in the edited NFDd2 parasites that express the 184F variant (slope  0.67  0.04),
compared with NYDd2 (P  0.04) or the Dd2 parental strain (86Y/Y184) (P  0.007)
(slope  0.53  0.04 and 0.51  0.03, respectively), suggesting a nonnegligible influ-
ence of amino acid position 184 in PfMDR1 transport capacity (Fig. 3B).
To determine whether there were PfMDR1 haplotype-specific differences in the
accumulation of Fluo-4, we measured the Fluo-4 intensity of the pfmdr1-edited lines
and the W2 comparator strain after normalizing to the fluorescence intensity of Dd2
parasites after 240 min. The results showed that the N86 allele has an important role in
the modulation of the PfMDR1 transporter since N86 edited parasites accumulated
more Fluo-4 compared with the Dd2 parental strain containing the 86Y allele (P  0.03).
Furthermore, edited NFDd2 parasites containing the N86/184F haplotype accumulated
FIG 3 Evaluation of Fluo-4 accumulation. (A) Representative images of Dd2 and pfmdr1-edited lines (NYDd2 and
NFDd2) stained with Fluo-4 AM (green). BF, Bright field. The bar measures 5 m. (B) PfMDR1-associated dynamic
transport between the strains Dd2, NFDd2, NYDd2, and W2, as determined by linear regression of the Fluo-4 probe
signal over time. Data are shown as comparative mean  SEM (error bars) (as a percentage) from four independent
assays. Linear regression and slopes extracted from each equation. # indicates a significant difference in the rate
of Fluo-4 accumulation in NFDd2 parasites compared with the rates obtained in NYDd2 and Dd2 parasites (P  0.04
and P  0.007, respectively). (C) Normalized Fluo-4 AM intensities (as a percentage) in all parasite strains measured
at 240 min. The fluorescence intensities exhibited by NFDd2 and NYDd2 and the W2 strain were normalized to the
parental Dd2 parasite strain (indicated in the graph as the baseline [y  0]). Values below or greater than zero
indicate a decrease or increase, respectively, in the percentage of accumulated fluorescence compared with Dd2
parasites. Mann-Whitney U tests were used to assess statistically significant differences between the NFDd2, NYDd2,
Dd2, and W2 parasites in panels B and C (*, P  0.05). (D) Normalized Fluo-4 intensities (as a percentage) in the
absence (untreated control) and presence of elacridar (ELC, 0.1 M) and verapamil (VP, 0.8 M). Results were
normalized to untreated controls (indicated in the graph as the baseline [y  0]). Values below or greater than zero
indicate a decrease or increase, respectively, in the percentage of accumulated fluorescence compared with
untreated controls. The means plus SEM of four independent measurements are shown. Mann-Whitney U tests
were used to assess statistically significant differences between untreated and treated parasites (*, P  0.05).
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more Fluo-4 in their DVs than edited NYDd2 parasites (haplotype N86/Y184) (P  0.03).
W2 parasites, which harbor a single genomic copy of the pfmdr1 gene with the
86Y/Y184 haplotype, accumulated less Fluo-4 (P  0.03) relative to the parental Dd2
control strain that expresses four copies with the same 86Y/Y184 haplotype (Fig. 3C).
The influence of pfmdr1 copy number on the import of Fluo-4 into the parasite DV
observed herein confirms previous reports where a parasite strain harboring only one
pfmdr1 copy accumulated less Fluo-4 compared with parasites expressing two copies
(31).
To determine whether the changes in Fluo-4 accumulation were related to the
PfMDR1 haplotype, we used elacridar (ELC) as a tool, since it is a well-established
inhibitor of P-glycoprotein type ABC transporters (46). We measured the fluorescence
intensity of Fluo-4 in NFDd2, NYDd2, or Dd2 parasites in the presence of ELC. Data were
normalized to the respective untreated controls (NFDd2, NYDd2, or Dd2; indicated in
Fig. 3D as the baseline [y  0]). We observed a significantly decreased Fluo-4 accumu-
lation in ELC-treated parasites compared with untreated controls (P  0.03). The
addition of verapamil (VP), a calcium ion channel blocker that reverses parasite resis-
tance to CQ, led to a significant reduction of Fluo-4 accumulation only in the edited
NFDd2 line compared to untreated NFDd2 (P  0.03), suggesting a possible interplay
between the PfMDR1 and PfCRT transporters in 184F-expressing parasites (Fig. 3D). The
addition of VP produced a trend toward more Fluo-4 accumulation in NYDd2 and
Y184-harboring Dd2 parasites compared with NFDd2. Nevertheless, despite having a
different trend, the quite large standard error of the mean (SEM) made these results
inconclusive.
Amplified pfmdr1 with the N86 allele decreases parasite susceptibility to
antimalarials. We determined the impact of the N86 allele in the genomic context of
multicopy pfmdr1 on parasite susceptibility to antimalarial drugs. Replacement of the
86Y variant present in Dd2 with N86 in each of the four pfmdr1 copies (edited parasite
line NYDd2) induced a significant increase in the half-maximal in vitro growth inhibitory
concentration (IC50) values for MFQ (2.5-fold, P  0.02) and LMF (2.4-fold, P  0.02), as
well as for dihydroartemisinin (DHA) (2.3-fold, P  0.05) (Fig. 4 and Table 2). A reduction
in the IC50 values for MFQ (6.1-fold, P  0.05) in W2 (a single pfmdr1 copy strain with
the 86Y/Y184 haplotype) compared with Dd2 parasites was observed. These data show
a clear role of pfmdr1 gene amplifications, particularly those encoding the N86 allelic
variant, in the multidrug resistance phenotype.
In the case of QN, the replacement of 86Y to N86 in multicopy pfmdr1 resulted in a
decrease of IC50 values in the NFDd2 and NYDd2 lines (1.6-fold, P  0.02) relative to the
parental Dd2 strain.
Our assays revealed no differences in susceptibilities to the quinoline drugs CQ,
monodesethyl-ADQ (md-ADQ), piperaquine (PPQ), and pyronaridine (PND) in the con-
text of multicopy pfmdr1 containing N86.
The N86/184F PfMDR1 haplotype decreases parasite susceptibility to LMF.
Analysis of the MalariaGEN P. falciparum Community Project data predicted a preva-
lence of the pfmdr1 184F allele in Africa of 58.6% (184F, 1,438/2,454 genomes sampled
between 2002 and 2015) and 36% (184F, 858/2,403 between 2002 and 2015) in
Southeast Asia, regardless of the number of pfmdr1 copies (Table S1 and Fig. S1). The
frequency of the 184F allele increased worldwide over the years analyzed (Table S1 and
Fig. S1). Here, in the context of amplified pfmdr1 gene copies, we observed up to
1.7-fold (P  0.002) decreased susceptibility to LMF in edited parasites expressing the
N86/184F haplotype compared with isogenic parasites expressing the N86/Y184 hap-
lotype (Fig. 4 and Table 2). This suggests a specific effect of the 184F allele in conferring
resistance to LMF in parasites that harbor amplified copies of pfmdr1.
PfMDR1-mediated resistance phenotypes are modulated by VP and ELC. We
investigated the potential interplay between PfMDR1 and PfCRT transporters in mod-
ulating parasite susceptibility to antimalarials using the PfCRT and P-type ATPase
transporter inhibitors VP and ELC, respectively. All the parasite strains used in this study
express the CVIET variant at amino acid positions 72 to 76 of PfCRT (Table 1). In the
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presence of VP, the multicopy pfmdr1 Dd2 strain and the edited parasites lines NFDd2
and NYDd2 exhibited increased susceptibility to the 4-aminoquinolines CQ and md-ADQ
compared with the respective untreated parasites, with 5-fold and 2- to 3-fold changes,
respectively. Increases in susceptibility were also obtained with QN and MFQ in the
presence of VP compared with untreated parasites, with N86 producing higher fold
changes than 86Y (QN, NFDd2  2.8-fold, NYDd2  3.1-fold, and Dd2  2.2-fold; MFQ,
NFDd2  4.1-fold, NYDd2  5.0-fold, and Dd2  2.9-fold) (Table 2). The differences in
fold changes observed in the presence of VP can be explained by the differential basal
levels of susceptibility to QN and MFQ in the absence of VP in NFDd2, NYDd2, and Dd2
parasites (Fig. 4). For LMF, VP sensitized NFDd2 and NYDd2 parasites up to twofold with
no effect observed on unedited Dd2 parasites compared with untreated parasites
(Table 2).
Comparing the IC50 values between the three haplotypes in the presence of VP, a
significant increase in QN susceptibility was observed in NFDd2 and NYDd2 parasites
compared with the Dd2 parental control (NYDd2 IC50  60.6 nM versus Dd2 IC50 
111.5 nM, P  0.01; NFDd2 IC50  65.3 nM versus Dd2 IC50  111.5 nM, P  0.02). For
MFQ and LMF, there was an increase in IC50 values for NFDd2 in the presence of VP
compared with VP-treated Dd2 parasites (MFQ NFDd2 IC50  7.5 nM versus Dd2 IC50 
4.2 nM, P  0.005; LMF NFDd2 IC50  4.4 nM versus Dd2 IC50  2.5 nM, P  0.01).
In the presence of the P-type ATPase transporter inhibitor ELC, the parasite lines
NFDd2 and NYDd2 exhibited 2.8-fold and 2.5-fold increased susceptibility to MFQ,
respectively, compared with the corresponding untreated parasites. It is interesting to
observe that ELC treatment reverted the MFQ IC50 values of NFDd2 and NYDd2 parasites
to the same level as that of Dd2 in the absence of ELC, validating the impact of the N86
pfmdr1 variant. ELC treatment did not significantly impact the susceptibility of Dd2,
NYDd2, or NFDd2 parasites to any of the other aryl-amino alcohols tested (i.e., QN and
LMF) or the 4-aminoquinolines (CQ and md-ADQ).
FIG 4 In vitro IC50 antimalarial response of NFDd2, NYDd2, Dd2, and W2 parasite strains. The antimalarial drugs (mefloquine [MFQ],
lumefantrine [LMF], dihydroartemisinin [DHA], piperaquine [PPQ], monodesethyl-amodiaquine [md-ADQ], chloroquine [CQ], quinine [QN],
and pyronaridine [PND]) were serially diluted, and after 72 h, the parasitemias were determined by flow cytometry after staining the
parasites with Mito Tracker Deep Red FM and SYBR green. IC50 values were calculated using nonlinear regression analysis. Data are means
plus SEM of at least three independent assays. Mann-Whitney U tests were used to assess statistically differences between Dd2 parental
strain and NFDd2, NYDd2, and W2 strains. *, P  0.05; **, P  0.01.
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DISCUSSION
The propensity of P. falciparum to develop antimalarial drug resistance underscores
the importance of characterizing its genetic basis. The amplification of pfmdr1 was the
first candidate mechanism implicated in CQ resistance (CQR) (47). Although we now
know that PfCRT is the primary determinant of CQR (48), pfmdr1 can modulate the
degree of resistance (49, 50). Several other studies have also shown that increased
pfmdr1 copy number decreases the parasite’s susceptibility to other antimalarials such
as MFQ, LMF, and ART (25, 38, 39). The worldwide spread of the pfmdr1 N-terminal 86Y
and 184F mutations have also been linked with differential responses to multiple
quinoline-based antimalarials and ART, both in vitro and in vivo (33, 36, 51–54). The
conjugation of these two types of polymorphisms (gene copy number and specific
sequence haplotypes) could modulate the P. falciparum response to these antimalarials.
Using data from the MalariaGEN P. falciparum Community Project, we determined
the worldwide prevalence and temporal changes of pfmdr1 copy number with specific
pfmdr1 N-terminal mutations. Furthermore, we measured the impact of these polymor-
phisms on solute kinetics of this transporter. We note that the MalariaGEN data from a
given period (2002 to 2015 in our case) relates to samples whose locations were
dependent on which partner studies were operative at the time (40). Temporal trends
in aggregated data should therefore be interpreted with caution. From 73 countries
where malaria is endemic with information on pfmdr1 amplifications and mutations at
amino acid positions 86 and 184, between 2002 and 2015, pfmdr1 amplification was
found almost exclusively in Southeast Asia, where we also observed a near fixation of
the N86 allele (Fig. 1; see also Table S1 and Fig. S1 in the supplemental material).
Considering the previous strong association of pfmdr1 amplifications and the N86 allele
with treatment failures that included MFQ or LMF (24, 25, 39), the frequencies observed
could be explained by the extensive use of artesunate plus MFQ and artemether plus
LMF in this region during that time period. Thailand, for example, is the country with
TABLE 2 Parasite responses to antimalarials in the presence of verapamil or elacridara
Antimalarial drug(s)
NFDd2 NYDd2 Dd2
Mean IC50 ( SEM) P value Mean IC50 ( SEM) P value Mean IC50 ( SEM) P value
MFQ 30.3 (1.1) 28.2 (1.0) 11.1 (1.8)
MFQ  VP 7.5 (0.4) 0.03 5.6 (0.8) 0.03 4.2 (0.1) 0.03
MFQ  ELC 10.9 (0.7) 0.03 11.1 (1.5) 0.03 7.7 (0.8) NS
LMF 9.7 (0.8) 5.6 (0.6) 2.3 (0.6)
LMF  VP 4.4 (0.3) 0.01 3.0 (0.2) 0.008 2.5 (0.3) NS
LMF  ELC 6.8 (1.7) NS 5.5 (0.8) NS 3.6 (0.4) NS
DHA 2.1 (0.4) 2.5 (0.4) 1.1 (0.2)
DHA  VP 1.2 (0.1) NS 1.3 (0.1) NS 1.0 (0.1) NS
DHA  ELC 1.5 (0.1) NS 1.8 (0.09) NS 1.2 (0.1) NS
PPQ 5.7 (0.6) 5.5 (0.6) 5.4 (0.5)
PPQ  VP 4.8 (0.9) NS 4.7 (0.2) NS 4.9 (0.5) NS
PPQ  ELC 5.9 (1.2) NS 5.1 (0.5) NS 5.0 (0.7) NS
md-ADQ 45.2 (1.7) 34.7 (3.4) 38.9 (3.0)
md-ADQ  VP 21.7 (1.0) 0.05 15.0 (2.8) 0.05 14.3 (1.2) 0.05
md-ADQ  ELC 39.6 (3.9) NS 35.4 (3.2) NS 43.3 (1.4) NS
CQ 254.1 (15.8) 255.1 (22.6) 191.2 (16.6)
CQ  VP 45.8 (2.7) 0.008 47.2 (2.8) 0.004 37.1 (2.6) 0.004
CQ  ELC 211.9 (18.4) NS 224.7 (19.2) NS 169.2 (6.6) NS
QN 183.1 (16.9) 190.0 (18.1) 252.8 (18.3)
QN  VP 65.3 (22.8) 0.003 60.6 (33.3) 0.003 111.5 (3.3) 0.003
QN  ELC 198.1 (39.6) NS 211.2 (57.6) NS 263.2 (19.5) NS
PND 4.1 (0.4) 4.4 (0.9) 4.4 (0.6)
PND  VP 2.5 (0.5) NS 3.4 (0.2) NS 3.0 (0.3) NS
PND  ELC 2.6 (0.6) NS 2.7 (0.3) NS 2.6 (0.2) 0.05
aNFDd2, NYDd2, and Dd2 parasites were incubated with mefloquine (MFQ), lumefantrine (LMF), dihydroartemisinin (DHA), piperaquine (PPQ), monodesethyl-
amodiaquine (md-ADQ), chloroquine (CQ), quinine (QN), and pyronaridine (PND) in the presence or absence of verapamil (VP) or elacridar (ELC). When incubated
with verapamil or elacridar, the antimalarial drugs used in study were serially diluted in the presence of 0.8 M VP or 0.1 M ELC for the 72-h in vitro growth
inhibition assays. Parasitemias were determined by flow cytometry after staining the parasites with Mito Tracker Deep Red FM and SYBR green. Mean  SEM IC50
values (nanomolar) were derived from three to five independent drug assays. Mann-Whitney U tests were used to assess statistically significant differences between
the untreated control parasites (Dd2, NYDd2, and NFDd2) and VP- or ELC-treated parasites. NS, not significant.
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the highest frequency of pfmdr1 amplifications, possibly reflecting the extensive use of
artesunate-MFQ as a first-line antimalarial treatment. Its failure during the following
years led to changes in treatment policy, with the adoption of dihydroartemisinin
(DHA)-PPQ as first-line therapy in 2008 (1, 2). This combination was associated with a
rapid decline in pfmdr1 copy number (55, 56), which could have resulted from PPQ-
mediated selection against multicopy pfmdr1 and/or selective pressure against multi-
copy pfmdr1 parasites that show some loss of fitness and can therefore be outcom-
peted by single-copy pfmdr1 parasites (2, 57, 58). In Cambodia, the loss of DHA-PPQ
efficacy led to the resumption of artesunate-MFQ use beginning in 2011, and this
combination retains good efficacy with pfmdr1 copy number generally remaining at
one (59).
In contrast, the MalariaGEN data illustrate pfmdr1 amplifications as a rare event in
Africa. The substantial use of CQ in the past and the current use of the ACT combination
artesunate-ADQ possibly contribute to this fact by selecting for deamplifications (60,
61). Furthermore, although artemether-LMF has been used for many years in Africa (62),
the lack of MFQ usage could partially explain the lack of pfmdr1 amplifications.
Nevertheless, it is conceivable that pfmdr1 amplifications may increase in prevalence in
Africa due to the widespread use of artemether-LMF (63, 64). The presence of the 86Y
allele in Africa could also contribute to the low prevalence of pfmdr1 amplifications as
this allele is present at a very low frequency worldwide when combined with pfmdr1
amplifications (6/597 genomes). Another factor could be related to the known fitness
cost associated with pfmdr1 amplifications, which manifests as decreased parasite
survival in the absence of drug pressure (58, 65). This feature is of particular relevance
in high transmission areas such as in sub-Saharan Africa. An interesting observation is
that within the MalariaGEN data, pfmdr1 amplifications with the haplotype 86Y/184F
were not present and despite several attempts to engineer this specific parasite line, we
were unsuccessful, possibly related to a genetic background that is detrimental for
survival.
Over time in Southeast Asia, we observed a clear selection of the 184F allele in
combination with pfmdr1 amplifications containing the N86 allele. Cambodia was the
country with the highest observed selection (25% [3/12] between 2002 and 2007% to
62% [43/69] between 2008 and 2010 and 85% [47/55] between 2011 and 2013) (Fig. 1).
It is important to note that at the same time that this takeover of the 184F occurs, the
prevalence of pfmdr1 duplications was actually shrinking due to the switch in first-line
treatment to DHA-PPQ. To better understand this selection of the N86/184F haplotype
in the context of amplified pfmdr1, we generated two edited lines representing the two
major geographic variants from Southeast Asia and studied the impact of the specific
haplotypes on antimalarial responses. The impact of these polymorphisms on PfMDR1
functional transport was also measured through accumulation of Fluo-4 in the DV of
the parasite (Fig. 3). This approach has been previously used for pfmdr1 variants and
revealed an important impact of the C-terminal amino acid 1042 on Fluo-4 transport
(22, 23). In these studies, although they used strains encompassing different haplotypes
in regard to the pfmdr1 N-terminal mutations, their direct impact was not evident. In
our Fluo-4 accumulation study with the Dd2 strain and isogenic lines differing only in
their pfmdr1 N-terminal residues at positions 86 and 184, we observed that parasites
expressing the mutations 86Y and 184F were capable of transporting Fluo-4 into the DV
(Fig. 3A). The N86 allele by itself impacted Fluo-4 transport capacity, with significant
differences obtained between the parental Dd2 strain and NYDd2 (Fig. 3C). Transport
studies in Xenopus oocytes have also provided evidence of the impact of polymor-
phisms at position 86 on the ability of PfMDR1 to transport different drugs. A single
amino acid alteration from N86 to 86Y in PfMDR1 resulted in loss of the ability to
transport QN and CQ (21). Consistent with this observation, the presence of the N86
allele induced a significant impact on antimalarial responses (Fig. 4). We were able to
confirm the involvement of residue 86, specifically in the context of multicopy pfmdr1,
in modulating parasite susceptibility to multiple antimalarials. Gene-edited parasites
with amplified pfmdr1 harboring the N86 allele displayed decreased susceptibility to
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MFQ, LMF, and DHA as well as increased susceptibility to QN, compared to the unedited
Dd2 parental line possessing the 86Y allele (Fig. 4). These findings are consistent with
our previous allelic exchange work that used ZFN-edited parasites expressing the 86Y
variant in the context of single-copy pfmdr1 (30). This observation explains the selection
of the N86 allele after treatment with artemether-LMF (26–28) and corroborates with
N86 being a risk factor for recrudescence following treatment with artemether-LMF
compared with P. falciparum infections containing 86Y (29).
The pfmdr1 184F mutation adds to the role of polymorphisms at position 86 in
modulating parasite drug resistance and transport. We found that edited parasites
harboring the N86/184F haplotype accumulated more Fluo-4 inside the DV compared
to edited parasites with the N86/Y184 haplotype, accompanied by faster kinetics of
PfMDR1-mediated transport activity (Fig. 3B). A previous in silico PfMDR1 model
proposed that the 184F allele alters the parasite’s response by an allosteric effect on
transport kinetics, independent from drug-binding capacity (20). Our gene-edited
parasites expressing amplified pfmdr1 with the N86/184F haplotype displayed a mild
but significant decreased susceptibility to LMF (1.7-fold) compared to those harboring
the PfMDR1 N86/Y184 haplotype or to the 86Y/Y184-bearing parental Dd2 parasites
(Fig. 4). The mild but significant fold difference herein observed was not detected in our
previous allelic exchange work for the same haplotype, possibly due to the single
pfmdr1 copy present in the NF10 and KC5 strains precluding sufficient expression to
display this phenotype (30). In vivo selection of the 184F allele has been reported,
typically along with other pfmdr1 alleles, after artemether-LMF treatment. Most notably,
the N86/184F haplotype was selected upon the regular six-dose therapy with
artemether-LMF (26, 27). In their analysis of two clinical trials after artemether-LMF
treatment, Malmberg et al. demonstrated that recrudescent infections harboring the
PfMDR1 N86/184F haplotype, in the context of a single pfmdr1 copy, were able to
endure higher blood LMF concentrations (28). Together with our results that examine
the role of copy number, these in vivo data suggest that although the pfmdr1 184F
allele might not be the primary determinant for parasite resistance, it could provide a
complementary genetic background that facilitates the acquisition of multidrug-
resistant phenotypes, possibly leading to the specific haplotype selection observed in
Southeast Asia (Fig. 1).
The interplay between PfMDR1 and PfCRT transporters in modulating parasite
susceptibility to antimalarials was also evident in this work (Table 2). Heightened
susceptibilities of NFDd2, NYDd2, and Dd2 P. falciparum lines to MFQ, md-ADQ, CQ, and
QN were affected by VP as previously observed in other genetic backgrounds (48, 66).
The role of PfMDR1 in the parasite’s response to QN remains unclear, but mutant PfCRT
is known to contribute to QN resistance (67). Our results with VP also suggest a role for
PfCRT. We note that VP increased susceptibility to LMF only in the edited parasites and
not in the unedited Dd2 control. Prior data showed selection of the pfcrt CQ-sensitive
wild-type K76 allele occurs upon artemether-LMF treatment, as confirmed in vitro using
allelic exchange (68). In the case of LMF, VP might have a greater effect on PfMDR1 in
the context of N86, since we observed that VP decreased Fluo-4 accumulation in the
parasite’s DV in N86 parasites (Fig. 3D). This observation would explain the increased
parasite susceptibility to LMF upon VP exposure.
In the presence of ELC, decreased MFQ IC50 values were observed in NFDd2 and
NYDd2 edited parasites, reinforcing the hypothesis that not only are pfmdr1 amplifica-
tions associated with MFQ resistance (24, 25, 39) but also that the pfmdr1 N86 allele is
a key mediator of MFQ susceptibility. These findings are in line with the MalariaGEN
data showing that almost all parasites that contain pfmdr1 amplifications are in the
context of the pfmdr1 N86 allele.
In conclusion, our in vitro parasite drug susceptibility data using pfmdr1 gene-edited
parasites reinforce the role of both pfmdr1 CNV and haplotype variation in modulating
parasite responses to multiple first-line antimalarial drugs. Our investigation highlights
the steady geographic expansion of a parasite population harboring a pfmdr1 gene
amplification with the N86/184F haplotype in Southeast Asia, which we show has a
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proven higher DV transport efficacy. These data could help tailor and optimize anti-
malarial drug usage in different areas where malaria is endemic by taking into account
the regional prevalence of pfmdr1 polymorphisms.
MATERIALS AND METHODS
Geographical distribution of P. falciparum isolates carrying pfmdr1 copy number amplifica-
tions and the mutations N86Y and Y184F. Genome analysis used data generated by the Wellcome
Sanger Institute as part of the MalariaGEN Plasmodium falciparum Community Project version 6 (https://
www.malariagen.net/resource/26) (40). Sample metadata were obtained from https://www.malariagen
.net/resource/26 and were combined with the genotype data for pfmdr1 polymorphisms at codons 86
and 184. pfmdr1 copy number was determined using a combination of a coverage-based approach and
a method based on position and orientation of reads near discovered duplication breakpoints as
described elsewhere (41). The map presented in Fig. 1 was created using mapchart.net, geo-referencing
the pfmdr1 gene copy number prevalence in the region.
Parasite culture. The Dd2 strain (MRA-156, MR4-Malaria Resources) was maintained at 4% hemat-
ocrit with human red blood cells in RPMI 1640 medium supplemented with 2 mM l-glutamine, 200 M
hypoxanthine, 0.25 g/ml gentamicin, 25 mM HEPES, 0.2% NaHCO3, and 0.25% Albumax II (Invitrogen;
ThermoFisher Scientific). Red blood cells were isolated either from whole blood or from buffy coat
samples provided by healthy donors of all blood types. Parasite cultures were maintained at 37°C under
a humidified controlled atmosphere of 5% O2/5% CO2/90% N2. Parasite growth was monitored by
inspecting Giemsa-stained blood smears. Parasite synchronization was performed with 5% sorbitol for
15 min at 37°C. To obtain highly synchronous cultures, sorbitol was added to the culture to eliminate
trophozoites. This was repeated 20 h and 44 h after the initial treatment to obtain 4-h postinvasion ring
stages that then mature into trophozoites, which were used to measure Fluo-4 fluorescence.
P. falciparum transfections. The previously designed plasmids pmdr1NF and pmdr1NY (30) were used
to transfect Dd2 parasites. Briefly, we introduced the desired mutations into the endogenous pfmdr1
locus of Dd2 parasites using ZFN-mediated genome editing. These customized ZFNs bind on opposite
strands of pfmdr1, producing a double-stranded break 42 bp downstream of the start codon. DNA repair
proceeds via homologous recombination, as P. falciparum lacks the nonhomologous end-joining path-
way (69). Our homology-driven repair template consisted of a 2.4-kb pfmdr1 fragment that encompassed
codons 86 and 184 (30).
Ring-stage cultures at 5% parasitemia were electroporated with 50 g of plasmid DNA diluted in
Cytomix (120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES
[pH 7.6]). The plasmids express the human dihydrofolate reductase (hDHFR) selectable marker, which
confers resistance to the antifolate drug WR99210. To allow transient expression of the ZFNs, WR99210
selection was applied to transfected cultures beginning 24 h postelectroporation and maintained for
6 days to select for edited parasites. Parasites were visible microscopically 6 weeks postelectroporation
and screened for editing events via blood PCR using the primers p3 and p4. Positive bulk cultures were
cloned by limiting dilution in 96-well plates. After 15 days, cloning plates were screened and parasite-
positive wells were screened for ZFN-mediated editing by blood PCR amplification using a supreme
NZYTaq II 2 Green Master Mix (NZYTech, Lisbon, Portugal) and the p3 and p4 primers (see Table S2 in
the supplemental material). The donor sequence includes silent mutations that create a SmlI restriction
site, which was used to screen the PCR products by restriction fragment length polymorphism (RFLP)
analysis (a 1.3-kb band obtained with primers P3 plus P4 [Table S2] that forms a doublet at 667/669 bp
with SmlI in edited parasites). The BstEII restriction site is present only in the nonedited genomic pfmdr1
sequence and was therefore used as a control in the PCR-RFLP assay (Fig. 2B). Editing events at codons
86 and 184 were confirmed by Sanger sequencing using the p5 primer (Table S2). Successfully edited
parasite lines (NFDd2 and NYDd2) were expanded and cryopreserved.
In this work, we have compared the edited NFDd2 and NYDd2 lines to an unedited Dd2 parental
control harboring the 86Y/Y184 haplotype. An edited Dd2 control was not performed in this study, since
the plasmids used herein to edit Dd2 parasites were the same as those used previously by our group (30).
In that study, we demonstrated that gene-edited control parasites carrying only silent ZFN binding site
mutations did not alter the parasite’s response to antimalarial drugs compared with unedited parental
lines.
Copy number analysis of pfmdr1. Genomic DNA from parental control Dd2 and pfmdr1-edited
parasites (NYDd2 and NFDd2) were extracted using the NZY Blood gDNA isolation kit (NZYTech, Lisbon,
Portugal) with RNase treatment. Copy numbers of the pfmdr1 gene were determined using a NZYSpeedy
Green Master Mix (2) (NZYTech, Lisbon, Portugal). The amplification reactions were carried out in 20-l
volumes in a 96-well plate using 10 ng of genomic DNA, 400 nM each forward and reverse primer, and
the master mix. The P. falciparum -tubulin gene was used as the housekeeping control gene. The pfmdr1
and pf-tubulin forward and reverse primers (Table S2) were previously designed (70). For each run, 3D7
was used as a single-copy-number control for pfmdr1. Thermal cycling was performed at 98°C for 3 min,
followed by 44 cycles with 1 cycle consisting of 98°C for 15 s, 59°C for 30 s, and 72°C for 25 s using the
Bio-Rad CFX96 real-time system C1000 thermal cycler. Results were analyzed by the 2  ΔΔCt (threshold
cycle) method of relative quantification. The ΔΔCt calculation was used as follows ΔΔCt  (Ct of pfmdr1 – Ct
of Pf-tubulin) – (Ct of pfmdr1 – Ct of Pf-tubulin)y, where  is sample and y is P. falciparum 3D7 strain.
The average gene copy number was calculated from three biological replicates, each with technical
replicates run in duplicate.
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Live-cell imaging of Fluo-4 accumulation in the DV. Fluorescence microscopy was used to
evaluate the accumulation site of Fluo-4 AM (Invitrogen; ThermoFisher Scientific) in different parasite
strains in trophozoite stages. Synchronized trophozoite cultures, at 2% parasitemia and 2% hematocrit,
were washed with RPMI 1640 medium and loaded with 5 M Fluo-4 diluted in RPMI 1640 medium.
Parasites were incubated for 240 min at 37°C in a humidified controlled atmosphere of 5% O2/5%
CO2/90% N2. After 240 min, the parasites were washed twice with 1 phosphate-buffered saline (PBS)
and transferred onto a slide. Fluorescence microscopy was performed using an Olympus BX61 micro-
scope equipped with a visible light laser, and the images were recorded with a digital camera (DP70). The
parasites incubated with Fluo-4 were excited at 488 nm with the emission in the green channel (505-nm
filter), and an exposure time of 457 ms was applied to obtain the images. Single images were obtained
using a 100 objective lens. Regions of interest within the infected RBC, including the parasite cytosol
and the parasite DV, were recorded with Cell^P software (Electro optics, UK) and the image overlays were
obtained using Image J software version 1.52a.
Quantification of Fluo-4 accumulation by flow cytometry. Flow cytometry was used to quantify
Fluo-4 accumulation in NFDd2, NYDd2, Dd2, and W2 parasites. Parasite labeling and evaluation of Fluo-4
accumulation were performed as described previously (22) with minor modifications. Briefly, synchro-
nized trophozoites were incubated with 5 M Fluo-4 AM (Invitrogen; ThermoFisher Scientific) for 240 min
at 37°C in an airtight environment flushed with 5% O2/5% CO2/90% N2. The level of fluorescence in
infected RBCs was recorded by flow cytometry every 15 min until 120 min, and every 30 min thereafter
up to a total incubation period of 240 min (see Fig. S2 in the supplemental material). This assay was
followed by live-cell imaging at all time points described above to visualize when the Fluo-4 probe
accumulated in the parasite DV (Fig. S2). Fluo-4 accumulation in the DV, presented in Fig. 3, was
confirmed by fluorescence microscopy before flow cytometry. Thirty minutes before the incubation
ended, parasites were loaded with 1.6 M Mitotracker Deep Red FM (Invitrogen; ThermoFisher Scientific).
For flow cytometry, labeled parasites were excited at 488 nm and 633 nm to detect Fluo-4 and
Mitotracker Deep Red FM, respectively. Forward (FSC) and side scatterplots (SSC) were used to define the
RBC populations followed by gating double-positive populations for Fluo-4 and Mitotracker Deep Red
FM. Approximately 200,000 events were read per experimental condition, and the mean Fluo-4 intensity
was calculated for each parasite strain. Due to intrinsic variability observed in the different replicate
assays, the fluorescence intensity of NFDd2, NYDd2, and W2 was normalized to the Dd2 parental control
(i.e., Dd2 corresponding to 100%; indicated in the graph as the baseline [y  0]). Values below zero
indicate a decrease in the percentage of accumulated fluorescence compared with Dd2 parasites,
whereas values above zero indicate an increase.
Fluo-4 accumulation in NFDd2, NYDd2, and Dd2 parasites was also measured in the presence or
absence of ELC, an inhibitor of P-type ATPase transporters, including PfMDR1 (and others, e.g., ABCI3),
or VP, a calcium channel blocker that functions as a CQ resistance reversal agent. Briefly, synchronized
trophozoites were washed with RPMI 1640 medium and preincubated for 10 min with ELC (0.1 M) or VP
(0.8 M). Sample preparation and flow cytometry were performed as described above. The fluorescence
intensities of NFDd2, NYDd2, and Dd2 in the presence of VP or ELC were normalized to the respective
untreated controls (indicated in the graph as the baseline [y  0]). Values below zero indicate a decrease
in the percentage of accumulated fluorescence compared with untreated controls, while values above
zero indicate an increase.
In vitro antimalarial drug assays. Drug susceptibility assays using CQ, DHA, MFQ, QN, LMF,
md-ADQ, PPQ, and PND in the absence or presence of ELC (0.1 M) or VP (0.8 M) (48) were run for the
edited parasite lines NFDd2 and NYDd2, the parental control strain Dd2, and the W2 strain. These assays
were performed using a published flow cytometry-based method (30). Briefly, synchronized ring-stage
parasites at 0.2% starting parasitemia and 1% hematocrit were incubated in the presence of different
concentrations of drug (across a dilution range of twofold; 12-point dilution series). After 72 h of
incubation at 37°C, samples were stained with 1.6 M Mitotracker Deep Red FM (Invitrogen; Thermo-
Fisher Scientific) and 2 SYBR green (for DNA staining) (Invitrogen; ThermoFisher Scientific) in 1 PBS
for 30 min and analyzed by flow cytometry to determine the parasite growth rates. Approximately
100,000 events were captured per well. In vitro IC50 values were calculated using nonlinear regression
analysis performed with GraphPad Prism 6 software.
Statistical analysis. Nonparametric, two-tailed Mann-Whitney U tests were used to assess IC50
antimalarial responses in the presence or absence of VP or ELC and Fluo-4 accumulation differences
between the NFDd2 and NYDd2, Dd2, and W2 parasite strains (normal distribution not assumed; performed
with GraphPad Prism Software).
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